0: The clinical information of hospitalized T2DM patients diagnosed with cancer was collected by reviewing medical records in Wuxi Peoples Hospital Affiliated to Nanjing Medical University from January 1, 2015, to June 30, 2020.
1: The following two cohorts were used to discover and validate biomarkers (Fig.
2: 1a): In the discovery set, a total of 20 serum samples from 5 healthy controls, 5 T2DM patients, 5 LAC patients at TNM stage 1 and 5 T2DM patients with LAC at TNM stage 1 (T2DM + LAC), which were submitted to SWATH-MS analysis; besides, 20 serum samples from T2DM patients and 20 serum samples from T2DM patients with LAC at TNM stage 1 were submitted for PRM-MS and ELISA analysis.
3: In the validation set, 20 serum samples from T2DM patients and 20 serum samples from T2DM patients with LAC at TNM stage 1 were collected for ELISA analysis.
4: Before analysis, the serum samples were kept at 80 C until use.
5: The study was approved by the Ethical Committee at Wuxi Peoples Hospital Affiliated to Nanjing Medical University, and the study was performed according to the Declaration of Helsinki.
